Skip to main content
. Author manuscript; available in PMC: 2015 Apr 22.
Published in final edited form as: J Patient Cent Res Rev. 2014 Spring;1(2):85–92. doi: 10.17294/2330-0698.1017

Table 4.

Median overall survival (OS) for CTC-positive and CTC-negative patients, and Cox proportional hazard ratio (HR) based on univariate analysis.

Author Year Median OS CTC<5, CTC=>5 (Month) 95% CI OS CTC<5, CTC=>5 (Month) Cox HR 95% CI (Cox HR)
Cristofanilli27 2004 >18, 10.1 N/A, (6.2–14.6) 4.26 N/A
Budd35 2006 22.6, 8.5 (20.1 to >25.0), (6.2–15.1) 3.18 (2.0–5.9)
Hayes29 2006 21.9, 10.9 (20.1 to >25), (6.4–15.1) 2.45 (1.6–3.7)
Cristofanilli57 2007 29.3, 13.5 N/A 2.3 (1.3–4.1)
De Giorgi31 2009 28.0, 6.2 (17.2 to >18.2), (5.9–15.7) 1.3 (0.7–2.6)
De Giorgi32 2010 34.8, 18.5 (23.5 to >40), (13.6–85.0) 2.2 (1.4–3.5)
Hartkopft36 2011 >24, 9.8 N/A, (7.3–12.3) N/A N/A
Giuliano33 2011 40.1, 21.9 (34.9–45.4), (15.6–28.4) 2.5 (1.6–3.9)
Muller76 2011 20.1, 14.0 (18.8–21.5), (12.8–21.5) 2.48 (1.5–4.4)
Piergra80 2012 >33, 19.8 N/A 2.4 (1.1–5.4)
Giordano77 2012 32.4, 18.3 (25.3–39.5), (15.5–21.1) 2.1 (1.7–2.7)
Wallwiener79 2013 >23, 18.01 N/A 4.8 (2.9–7.8)

CTC: circulating tumor cell; CI: confidence interval.